Tandem Diabetes Care has responded to an FDA recall notice that the organization calls its "most serious" after hundreds of injuries have been reported.

Tandem Diabetes Care announced that the FDA cleared its Control-IQ+ automated insulin delivery algorithm for people with type 2 diabetes.

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults ...

Tandem Diabetes Care, Inc. reported strong Q4 2024 earnings, but shares declined 30%. Click for my TNDM stock update in light ...

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery (AID) algorithm, Control ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...